Budesonide
An inhaled or oral corticosteroid used to control inflammation in conditions including asthma, COPD, allergic rhinitis, Crohn's disease, and ulcerative colitis. It has a high ratio of local to systemic effects due to extensive first-pass metabolism, reducing the risk of systemic corticosteroid side effects. It is available in inhaler, nasal spray, and oral formulations.
Molecular Weight
430.5000 g/mol
LogP
2.50
TPSA
93.10 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
2D Structure
Cite this structure
Embed this structure
SMILES
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
InChI
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
Molecular Formula
C25H34O6
HBD / HBA
2 / 6
Rotatable Bonds
4
Heavy Atoms
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An inhaled or oral corticosteroid used to control inflammation in conditions including asthma, COPD, allergic rhinitis, Crohn's disease, and ulcerative colitis. It has a high ratio of local to systemic effects due to extensive first-pass metabolism, reducing the risk of systemic corticosteroid side effects. It is available in inhaler, nasal spray, and oral formulations.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Budesonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1370. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281004. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="budesonide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/budesonide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/budesonide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/budesonide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="budesonide"></drugfyi-drug>